Health Canada approves updated Moderna vaccine for Omicron variant - CBC News | Canada News Media
Connect with us

Business

Health Canada approves updated Moderna vaccine for Omicron variant – CBC News

Published

 on


Health Canada has formally approved Moderna’s updated COVID-19 vaccine targeting the Omicron variant.

The vaccine, which has been approved for use in adults 18 and older, will become the first COVID-19 vaccine available in Canada that targets Omicron in addition to the original strain of the coronavirus.

In a decision summary made public Thursday, Health Canada said the new vaccine shows “significantly higher responses” to the Omicron BA.1 virus in comparison to Moderna’s original coronavirus vaccine, officially branded as Spikevax.

While the updated vaccine was developed to target the Omicron BA.1 variant, Health Canada says clinical trials suggest the new vaccine still elicits a “stronger immune response” against the more recent mutations of Omicron — BA.4 and BA.5 — which are now dominant.

“Results of exploratory analyses suggest that a second booster with Spikevax Bivalent would provide a superior neutralizing antibody response against BA.4/5 compared to a second booster with Spikevax Original,” reads a portion of the decision.

Health Canada also reports that “no new safety concerns have been identified in studies when compared to the currently approved Spikevax mRNA vaccine.”

The National Advisory Committee on Immunization recommends that the updated vaccine be offered to adults who are recommended to receive a fall booster dose.

NACI says adolescents between 12 and 17 with “moderately to severely immunocompromising conditions” and those who have elevated social risk factors could also be offered the vaccine.

WATCH: Health Canada’s Chief Medical Adviser Dr. Supriya Sharma says the updated vaccine will be effective against Omicron

Health Canada authorizes Moderna’s bivalent COVID-19 vaccine

11 hours ago

Duration 1:46

Health Canada’s Chief Medical Adviser Dr. Supriya Sharma says Moderna’s new bivalent vaccine will target both the old variant of COVID-19 as well as Omicron, the more recent one. It has been approved for use in Canadians 18 years and older.

The updated vaccine is a combination of two strains, also known as “bivalent” shots. It contains both the original vaccine formulation and protection against the original Omicron variant BA.1.

The new Moderna shot will be delivered in 50 microgram doses. Half of its contents target the original coronavirus strain while the other half target Omicron.

An initial shipment of 780,000 doses of the updated vaccine is set to arrive in Canada on Friday, Health Minister Jean-Yves Duclos said. An additional 10.5 million doses will be delivered by the end of September.

Deliveries to the provinces and territories, which oversee the administration of vaccines, are set to begin next week.

Duclos urged Canadians to sign up for booster shots quickly as summer comes to an end.

“This fall will be challenging, with the return of the flu and other respiratory diseases and people moving indoors,” Duclos told a news conference on Thursday afternoon.

Vaccines for newer Omicron strains may be coming

Both Moderna and Pfizer have developed even newer bivalent vaccines targeting the Omicron BA.4 and BA.5 strains, but the companies have not yet submitted those products for approval by Health Canada.

Njoo said that in choosing to approve Moderna’s BA.1-focused vaccine, the government considered the tools it has now “versus what might potentially happen in the future.”

“At the end of the day, we’re very comfortable with the fact that we have a good bivalent vaccine,” Njoo added.

The U.S. Food and Drug Administration announced Wednesday its approval of bivalent vaccines by Pfizer and Moderna that specifically target the more recent Omicron BA.4 and BA.5 strains.

Dr. Supriya Sharma, the chief medical adviser with Health Canada, said the agency expects to receive a submission from Pfizer as soon as next week for a bivalent vaccine targeting BA.4 and BA.5.

A new submission by Moderna for BA.4 and BA.5 is also expected within the next two weeks, Sharma said.

A spokesperson for Pfizer Canada told CBC News Wednesday that its submission to Health Canada for a BA.1-targeted bivalent vaccine is still under review and approval has not yet been granted.

WATCH: Infectious diseases physician says Canadians shouldn’t wait for updated boosters

Canadians at high risk urged not to wait for newer boosters: infectious disease specialist

8 hours ago

Duration 7:12

Infectious diseases physician Dr. Lisa Barrett is encouraged by approval of the new bivalent vaccine targeting Omicron BA.1. She says holding out for the next, more updated vaccine would be risky.

Angela Rasmussen, a virologist with the University of Saskatchewan’s Vaccine and Infectious Disease Organization, said the vaccine’s approval is an important development in Canada’s fight against COVID-19 —  even though the shot was developed for a strain that is no longer circulating widely.

“I do think it’s really important now for people to know that the BA.1 vaccine is still going to really improve immunity against the variants that are circulating,” Rasmussen told CBC News.

Another expert said Canadians should not wait for the perfect and most up-to-date vaccine, since they’ll likely need repeated COVID-19 immunizations in the future.

“That protection will not last. This will not be the last vaccine you get. So prepare, until we have vaccines that are better, to be vaccinated probably every six months,” said Dawn Bowdish, an immunologist at McMaster University.

Adblock test (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version